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Abstract
Background: HIV infection is a risk factor for Clostridium difficile infection (CDI) yet the immune deficiency predisposing
to CDI is not well understood, despite an increasing incidence of CDI among such individuals. We aimed to estimate
the incidence and to evaluate the risk factors of CDI among an HIV cohort in Italy.
Methods: We conducted a retrospective case-control (1:2) study. Clinical records of HIV inpatients admitted to the
National Institute for Infectious Disease “L. Spallanzani”, Rome, were reviewed (2002-2013). Cases: HIV inpatients
with HO-HCFA CDI, and controls: HIV inpatients without CDI, were matched by gender and age. Logistic regression
was used to identify risk factors associated with CDI.
Results: We found 79 CDI episodes (5.1 per 1000 HIV hospital admissions, 3.4 per 10000 HIV patient-days). The mean
age of cases was 46 years. At univariate analysis factors associated with CDI included: antimycobacterial drug exposure,
treatment for Pneumocystis pneumonia, acid suppressant exposure, previous hospitalization, antibiotic exposure, low
CD4 cell count, high Charlson score, low creatinine, low albumin and low gammaglobulin level. Using multivariate
analysis, lower gammaglobulin level and low serum albumin at admission were independently associated with
CDI among HIV-infected patients.
Conclusions: Low gammaglobulin and low albumin levels at admission are associated with an increased risk of
developing CDI. A deficiency in humoral immunity appears to play a major role in the development of CDI. The
potential protective role of albumin warrants further investigation.
Keywords: Clostridium difficile, HIV, AIDS, Case-control, Risk factors, Albumin, Gammaglobulins
Background
The incidence of Clostridium difficile infection (CDI) is
increasing worldwide in both the general population and
immunocompromised individuals [1-4].
Several factors have been associated with the risk of
CDI development, including: older age, antibiotic ex-
posure, acid suppressant exposure, inflammatory bowel
disease and immunosuppression [5-9]. Immune system
disorders are commonly documented as risk factors for
CDI and despite the advent of HAART, HIV seroposi-
tive individuals still represent a large immunosup-
pressed population. HIV infection has been found to be
a risk factor for CDI [5]. The role of cellular immunity
in the development of opportunistic infections is in-
creasingly understood, yet the immune deficiency pre-
disposing HIV-infected individuals to CDI has not been
adequately studied. There are no studies of CDI inci-
dence in HIV cohorts in Europe from the later HAART
era (i.e. post 2002); a time period that also represents a
considerable change in CDI epidemiology, including the
spread of hypervirulent strains and the emergence of
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increasing resistance rates to antimicrobials, in devel-
oped countries [10-12].
Our aim was to estimate the incidence of CDI among
HIV hospitalized patients, and to evaluate the associated
risk factors.
Methods
We collected data from 2002 to 2013 on CDI among
HIV-infected inpatients in our hospital, National Insti-
tute for Infectious Diseases “L. Spallanzani”, that is a
a referral center for HIV infected individuals in our
region of approximately 5.5 million inhabitants. CDI
cumulative incidence was expressed as CDI episodes
per 1000 hospital admissions of HIV-infected patients.
CDI incidence rate was expressed as the number of CDI
episodes per 10000 patient-days among HIV-infected
inpatients. Also data on CDI among non HIV-infected
inpatients were collected in the same period, in order
to compare the CDI trend in both the groups, HIV-
infected and not infected. In this case CDI cumulative
incidence was expressed as CDI episodes per 1000
hospital admissions of non-HIV infected patients and
CDI incidence rate was expressed as the number of CDI
episodes per 10000 patient-days among non HIV-
infected inpatients.
Moreover, we conducted a retrospective case-control
(1:2) study on adult HIV-infected patients. Cases were
defined as HIV inpatients with CDI; controls were HIV
inpatients without CDI that were hospitalized for at least
48 hours. Controls were patients without diarrhea or
with diarrhea but with negative toxin test for C. difficile.
Controls were randomly selected and matched for gen-
der, age (±5 years) and year of admission with cases.
Only healthcare facility (HCF)-onset, HCF-associated
(HO-HCFA) CDI were included in the study. HO-HCFA
CDI is defined as an episode of CDI occurring between
48 hours after admission and hospital discharge [13].
A CDI episode was considered as a positive C. diffi-
cile toxin assay in a stool sample from a patient with
diarrhea. Diarrhea was defined as ≥ 3 unformed stools
in a 24-hour period. The presence of toxin A and B was
tested through enzyme immunoassays (EIA) for A/B
toxins (C. difficile Tox A/B, TechLab, Blacksburg, VA).
CDI relapses were excluded from the analysis.
Demographic data (gender, age), fever (i.e. temperature >
38.3°C) and biochemical parameters (white blood cell
count, serum gammaglobulin level, serum albumin level,
serum creatinine level, CD4 cell count) measured at
admission were recorded. Gammaglobulin levels were
calculated through seroprotein electrophoresis from
total proteins. Normal range for serum albumin was
3.5-5.5 g/dl and for serum gammaglobulin 800-1600
mg/dl according to our laboratory. In addition the
following characteristics were compared between cases
and controls: Charlson’s score index, length of hospital stay,
antiretroviral treatment, antimycobacterial drug exposure,
prophylaxis with trimethoprim-sulfamethoxazole (TMP-
SMX) and/or azithromycin, chronic hepatitis C virus
(HCV) infection, treatment for Pneumocystis pneumonia,
antineoplastic chemotherapy, acid suppressants, prior hos-
pitalization (in the previous 8 weeks), prior antibiotic ex-
posure (in the previous 8 weeks), antibiotic exposure
during hospitalization and methadone treatment. The
recorded data were available for all cases and controls.
The study involved the analysis of existing clinical and
laboratory data that were anonymised before being in-
cluded in the study database. The study was approved by
the Ethics Committee of the National Institute for Infec-
tious Diseases “L. Spallanzani”.
Continuous variables are expressed as mean ± SD and
categorical variables as percentages.
Univariate analysis was performed for each recorded
variable, with the exception of mortality and length of
stay since such variables could be both a risk factor and/
or a consequence of CDI. Odds ratio (OR), with 95%
confidence interval, was calculated for qualitative vari-
ables; quantitative variables with normal distribution
were compared using the Student’s t test.
Multivariate regression analysis included all statistically
significant variables in univariate analysis and all clinically
relevant variables, whether statistically significant or not
[14]. The final model included the following variables: anti-
mycobacterial drugs exposure, treatment for Pneumocystis
pneumonia, acid suppressant use, previous hospitalization,
prior antibiotic exposure, antibiotic exposure during
hospital stay, CD4 cell count on admission, Charlson
score, serum creatinine on admission, serum albumin
on admission and gammaglobulin level on admission.
The Hosmer and Lemeshow test was applied to
estimate the goodness of fit for the model.
The statistical significance was set at P < 0,05.
The analysis was performed using STATA 11 MP
(StataCorp LP, College Station, Texas).
Results
From January 2002 to December 2013, 15 537 HIV-
infected patients were admitted to our Institute. The
distribution of HIV admission during this time is shown
in Figure 1A.
Seventy-nine cases of HO-HCFA CDI were identified
among HIV-infected inpatients during the study period.
Cumulative incidence was 5.1 per 1000 HIV hospital
admissions, with an incidence rate of 3.4 CDI cases per
10,000 HIV patient-days. Figure 1B compares the trend
of CDI incidence among HIV and non-HIV inpatients
through the study period.
Among CDI cases, 56 were male (71%), 23 were
female (29%) and the mean age was 46 years. Forty-three
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Figure 1 HIV admissions and CDI episodes: trends over time. A – HIV admissions per year; B – CDI episodes per year in HIV and non-HIV patients.
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percent of CDI cases had fever at diagnosis of CDI and
the mean white cell count at diagnosis was 7061 per
cubic millimeter (SD ±5167).
Regarding antibiotic exposure, carbapenem, fluoroquino-
lone and rifamycin exposures were significantly more
prevalent among cases compared to controls (Table 1).
Regimens used to treat CDI were metronidazole alone
for 42 patients (53%), oral vancomycin alone for 11 pa-
tients (14%). Fourteen patients received both vanco-
mycin and metronidazole (18%) and 12 patients (15% of
cases) received no CDI treatment during the hospital
stay because of death (1 patient) or voluntary discharge
(11 patients).
The mean duration of diarrhea among CDI cases was
13 days (SD ±12).
CDI occurred, on average, 12.7 days after admission
(range 3-50 days, SD ±11.8), with a median of 8 days
after the admission (IQR 4-16). The time to onset of
diarrhea during the hospital stay (from 48 hours after
the admission to the discharge) is illustrated in Figure 2.
In just over half of the patients (51.8%) (Figure 2,
dashed line) CDI occurred during the first 8 days after
hospital admission.
The risk factors analyzed for the 79 CDI cases and 158
matched control subjects are shown in Table 2. In uni-
variate analysis the following variables were significantly
associated with the development of CDI: antimycobacter-
ial drug exposure, treatment for Pneumocystis pneumonia,
acid suppressant exposure, previous hospitalization, prior
antibiotic exposure, antibiotic exposure during hospital
stay, low CD4 cell count, high Charlson score, low serum
creatinine level, low serum albumin level and low gamma-
globulin level.
On multivariable analysis (Table 3) low gammaglo-
bulin level and low serum albumin on admission were
independent factors associated with the development of
CDI among HIV infected individuals during
hospitalization.
Eleven patients (13.9%) among cases and 10 patients
(6.3%) among controls died during the hospital stay (p =
0.05). In 3 patients, in-hospital death was attributed to
CDI.
Discussion
HIV infection is an established risk factor for CDI and
the introduction of HAART has not effectively reduced
the risk of C. difficile among hospitalized HIV-infected
patients [15,16]. Although the incidence of HO-HCFA
that we found is lower (approximately 10 fold) as com-
pared to pre-HAART studies [17], in this study, we
found an increasing incidence in HO-HCFA CDI cases
among HIV infected patients admitted to our Institute
from 2008 to 2013, yet the number of admissions for
HIV related infections has been progressively decreasing.
Moreover we found that CD4 count was not associated
with CDI occurrence, whereas a lower level of gamma-
globulins was independently associated. Hypogammaglo-
bulinemia is a known predisposing factor for CDI in the
non-HIV population but an association has not been
evaluated in the HIV population [18-20].
However, in a study published in 1997, Barbut et al.
found that CD4 count was significantly associated with
CDI among HIV-infected patients, but gammaglobulin
levels were not evaluated among risk factors [21]. Simi-
larly in another recent study conducted in United States
evaluating the risk factors associated with CDI develop-
ment among HIV infected individuals, gammaglobulin
levels were not considered among variables to be
assessed as risk factors [4].
Table 1 Antibiotics taken before and during hospital stay, cases and controls
Antibiotics before hospital stay Cases (%) (n = 79) Controls (%) (N = 158) OR (95% CI) p
Fluoroquinolones 11 (14) 7 (4) 3.5 (1.2 – 11.0) 0.009*
3rd/4th gen. Cephalosporins 6 (7) 12 (8) 1 (0.3 – 3.0) 1
Carbapenems 1 (1) 2 (1) 1 (0.0 – 19.5) 1
Penicillins 4 (5) 12 (8) 0.6 (0.1 – 2.24) 0.464
Rifamycins 8 (10) 6 (4) 2.9 (0.8 – 10.3) 0.05*
Clindamycin 0 (0) 0 (0) \ \
Antibiotics during hospital stay
Fluoroquinolones 28 (35) 29 (18) 2.4 (1.3 – 4.7) 0.004*
3rd/4th gen. Cephalosporins 25 (32) 53 (34) 0.9 (0.5 – 1.7) 0.77
Carbapenems 18 (23) 9 (6) 4.9 (1.9 – 13.0) 0.0001*
Penicillins 15 (19) 27 (17) 1.1 (0.5 – 2.4) 0.718
Rifamycins 11 (14) 8 (5) 3.0 (1.1 – 9.1) 0.18
Clindamycin 3 (4) 1 (1) 6.2 (0.5 – 327.3) 0.075
*p ≤ 0.05.
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Host immunity, especially humoral responses to C. dif-
ficile toxins, is now believed to be a major determinant
of the consequences of C. difficile acquisition [22-24].
Indeed, in solid organ transplanted patients severe hypo-
gammaglobulinemia has been demonstrated to be a risk
factor for developing CDI [19].
Variation in antibody response may be a principal ex-
planation for the association of symptomatic C. difficile
infections with advanced age and immunodeficiency-
associated conditions, including HIV infection [25]. HIV
infection deranges both cellular and humoral immunity
and antigen-specific B cell memory responses are se-
verely impaired among HIV-infected individuals [26,27].
The ability of B cells to release immunoglobulins in vitro
has been shown to be dependent on functional CD4 cells
[28,29]. In studies which have demonstrated an associ-
ation between low CD4 cell count and CDI occurrence
it is possible that the concurrently impaired humoral im-
munity plays a role. Indeed, in our multivariate analysis,
when all potential risk factors, including both CD4 cell
count and gammaglobulin levels, are taken into account,
CD4 cell count per se is not significantly associated with
development of CDI [4,21]. Therefore, we hypothesise
that the measurement of CD4 cell count alone is serving
as a proxy marker for impaired humoral immunity and
that it is the latter which may be truly responsible for
the predisposition of HIV infected patients to acquire C.
difficile disease.
In the 1990s, C. difficile strains were often sensitive to
rifamycins (rifampicin, rifabutin) [30], yet more recently
there is growing evidence to show that several C. difficile
strains, mainly ribotype 027, are resistant to rifamycins
[31]. Therefore, the clinical use of such class of antibiotics
could be a potential risk factor for CDI. In particular, given
the spread of ribotype 027 in Italy [32] we think it is im-
portant to reassess the risk of CDI in patients receiving
antimycobacterial treatment. In our study 19% of cases
and 8% of controls were exposed to antimycobacterial
treatment (p = 0.02). Although on multivariate analysis,
“antimycobacterial drug exposure” as a risk factor for CDI
did not reach statistical significance, we think that further
studies should address this potential association.
Figure 2 Time to onset of diarrhea among hospitalized HIV patients with CDI.
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Low serum albumin is a well known risk factor for
CDI [33,34]. In our study albumin levels measured on
admission were lower in cases compared to controls (3
g/dl vs 3.4 g/dl), with a significant p-value at multivari-
ate analysis (p = 0.03). Since we assessed serum albumin
levels on admission, low albumin is not a consequence
of protein-losing enteropathy (i.e. low albumin is not
secondary to CDI) and should be considered a possible
predisposing factor for CDI development. Indeed, low
albumin could represent a marker of poor conditional
status (i.e. cachexia, malnutrition, wasting syndrome, cir-
rhosis, nephritic syndrome) [35]. Similar findings have
been recently reported by Kumarappa et al. in non-HIV
patients [36].
In this study, we observed a reduction in CDI inci-
dence from 2002 to 2008 and a progressive increase
from 2008 to 2013 that was similar to that observed
among non-HIV patients hospitalized between 2008 and
2013 (see Figure 1). We speculate that the reduction ob-
served in the first period reflects, in part, the observed
decrease in HIV patient admissions and partially to a re-
duction of opportunistic infections [37] and therefore,
antibiotic therapy. However, we hypothesize that the in-
creasing incidence observed from 2008 to 2013, in light
of the continued decrease in number of hospitalizations
among HIV patients, could be related to the emergence
of the C. difficile strain BI/NAP1/027. In support of this,
the first case reports of C. difficile 027 in Italy were pub-
lished in January 2010 [38] and in 2012 data from a
small case series demonstrated that 59% of the analyzed
strains were ribotype 027 [32].
Table 2 Demographic and clinical characteristics of incident CDI, cases and matched controls
Characteristic Categories Cases (N = 79) Controls (N = 158) Total (N = 237) Unadjusted comparison P value
Age, mean (years) 45,9 ± 9,3 45,4 ± 8,8 45,5 ± 8,9 MD – 0,6 (±1,2) 0,64
Gender, N (%) M 56 (70,1) 116 (73,4) 172 (72,6)
F 23 (29,1) 42 (26,6) 65 (27,4)
Hospitalization (days)^ 33,5 ± 26,6 14,2 ± 12,2 20,6 ± 20,3
Antiretroviral Treatment 55 (69,6) 96 (60,8) 151 (63,7) OR 1,5 (0,8 – 2,8) 0,20
Chronic HCV 39 (49,4) 67 (42,4) 106 (44,7) OR 1,3 (0,7 – 2,4) 0,31
Acid suppressants 36 (45,6) 51 (32,3) 87 (36,7) OR 1,8 (1,0 – 3,2) 0,04*
Antineoplastic chemotherapy 9 (11,4) 11 (7,0) 20 (8,4) OR 1,7 (0,6 – 4,8) 0,25
Previous hospitalization§ 45 (57,0) 55 (34,8) 100 (42,2) OR 2,5 (1,4 – 4,5) 0,01*
Antibiotic exposure 71 123 194 OR 2,5 (1,1 – 6,6) 0,02*
Death during hospitalization 11 (13,9) 10 (6,3) 21 (8,9)
Methadone therapy 17 (21,5) 37 (23,4) 54 (22,8) OR 0,9 (0,4 – 1,8) 0,74
CD4 on admission^ 188 ± 237 262 ± 259 238 ± 254 MD 74,3 (±34,8) 0,03*
Charlson score^ 6,8 ± 3,4 5,7 ± 3,7 6,1 ± 3,6 MD -1,1 (±0,5) 0,027*
HIV RNA, median 20.610 2.214 3.601 MD -15.935 (±33.975) 0,640
Serum Creatinine on
admission (mg/dl)^
1,3 ± 1,8 0,9 ± 0,7 1,1 ± 1,2 MD 1,1 (±0,1) 0,036*
Serum Albumin on
admission (g/dl)^
3,0 ± 0,7 3,4 ± 0,7 3,2 ± 0,7 MD 0,4 (±0,1) <0,001*
Gammaglobulins on
admission (g/dl)^
1,6 ± 0,7 1,9 ± 1,0 1,8 ± 0,9 MD 0,2 (±0,1) 0,05*
Extreme values (outliers: 2 upper and 2 lower) were excluded; there are no missing data; ^: mean; §: 8 weeks before; *: P value≤ 0,05; Antibiotic exposure was evaluated
until the development of diarrhea among cases and until the discharge for controls; MD: mean difference and standard deviation; OR: Odds ratios and 95% confidence
intervals; P: prophylaxis; PCP: Pneumocystis pneumonia; TMP-SMX: trimethoprim-sulfamethoxazol.
Univariate analysis for factors associated with CDI in HIV-infected hospitalized individuals
Table 3 Independent risk factors for CDI among HIV-
infected inpatients as defined by multivariate logistic
regression
Variable OR (95% CI) P
Acid suppressants 1.23 0.67-2.26 0.49
Previous hospitalization (<8 weeks) 1.69 0.92-3.11 0.09
Antibiotic exposure 2.02 0.83-4.91 0.12
CD4 cell count on admission 0.99 0.99-1.00 0.25
Charlson score 1.02 0.94-1.12 0.53
Serum Creatinine on admission (mg/dl) 1.09 0.86-1.39 0.45
Serum Albumin on admission (g/dl) 0.61 0.39-0.96 0.03*
Gammaglobulins on admission (g/dl) 0.68 0.48-0.96 0.03*
Antibiotic exposure was evaluated until the development of diarrhea among
cases and until hospital discharge for controls. CI: confidence intervals; OR:
odds ratio; * p < 0.05.
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Whilst this case:control study has yielded important
insights into potential mechanisms for the increased
propensity to CDI in HIV infected patients, our retro-
spective study has some limitations. We only considered
one episode of CDI per patient thus recurrent disease was
not evaluated. We did not evaluate community acquired
CDI, but we must consider that different risk factors may
be important outside the nosocomial environment. In our
hospital, the number of diagnostic tests for CDI increased
during the study period (in particular from 2006), there-
fore CDI episodes since this time could be potentially
over-represented. In addition we only used the EIA toxins
detection as diagnostic test for CDI; this test has a low
sensitivity therefore it is possible that patients with true
CDI but with false negative toxin EIA may have been in-
appropriately included as control. Moreover we did not
perform culture for C. difficile and we could not ascertain
if the CDI rise has been due to one/few clonal lineages of
C. difficile. Finally, selection bias is a risk in case:control
studies and we strived to minimize this by including all
known CDI cases during the study period and random
selection of controls.
Conclusions
In our study, lower gammaglobulin and albumin levels
are associated with the developing of CDI. It remains
vital that the immune constitutents that play a role in
susceptibility to CDI are further elucidated. Strategies
to improve humoral immunity and albumin status in
patients with immune dysfunction should be further
explored in an effort to reduce the incidence of CDI.
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